Samet Yilmaz

Samet Yilmaz

Auto-generated profile, based on publicly available information

Samet Yilmaz

Cardiology, Pamukkale University , Türkiye

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2017 in Biomarkers in Medicine
Verified
Journal Article
Closed access
DVDemir Vahit
Demir Vahit
MAMehmet Kadri Akboga
Mehmet Kadri Akboga
YSYilmaz Samet
Yilmaz Samet
EHEde Hüseyin
Ede Hüseyin
Aim: We aimed to investigate the relationships between metabolic syndrome (MS) and monocyte to high density lipoprotein cholesterol ratio (MHR) and lymphocyte-to-monocyte ratio (LMR). Methods: 762 patients (n = 371 MS present and n = 391 MS absent) were enrolled. Results: MHR was significantly higher [13.9 (10.5–18.1) vs 11.1 (8.0–14.8); p < 0.001], whereas LMR was significantly lower [4.5 (3.6–5.7) vs 3.6 (2.9–4.8); p < 0.001] in patients with MS. LMR [OR: 0.796 (95% CI): 0.711–0.892); p < 0.001], MHR [OR: 1.052 (95% CI: 1.018–1.088); p = 0.003] and C-reactive protein [OR: 1.048 (95% CI: 1.032–1.065); p < 0.001] remained as independent variables for the presence of MS. Conclusion: The present study shows that both LMR and MHR may be novel and useful indicators of MS.

1 January 2015 in Korean Circulation Journal
Verified
Journal Article
Open access
SYSamet Yilmaz
Samet Yilmaz
Ugur CanpolatUgur Canpolat
Ugur Canpolat
SASinan Aydogdu
Sinan Aydogdu
HAHanna Emily Abboud
Hanna Emily Abboud
Patients with diabetes have an increased risk for development of cardiomyopathy, even in the absence of well known risk factors like coronary artery disease and hypertension. Diabetic cardiomyopathy was first recognized approximately four decades ago. To date, several pathophysiological mechanisms thought to be responsible for this new entity have also been recognized. In the presence of hyperglycemia, non-enzymatic glycosylation of several proteins, reactive oxygen species formation, and fibrosis lead to impairment of cardiac contractile functions. Impaired calcium handling, increased fatty acid oxidation, and increased neurohormonal activation also contribute to this process. Demonstration of left ventricular hypertrophy, early diastolic and late systolic dysfunction by sensitive techniques, help us to diagnose diabetic cardiomyopathy. Traditional treatment of heart failure is beneficial in diabetic cardiomyopathy, but specific strategies for prevention or treatment of cardiac dysfunction in diabetic patients has not been clarified yet. In this review we will discuss clinical and experimental studies focused on pathophysiology of diabetic cardiomyopathy, and summarize diagnostic and therapeutic approaches developed towards this entity.

18 August 2016 in Biomarkers in Medicine
Verified
Journal Article
Closed access
SYSamet Yilmaz
Samet Yilmaz
MAMehmet K Akboga
Mehmet K Akboga
FSFatih Sen
Fatih Sen
KBKevser G Balcı
Kevser G Balcı
DADursun Aras
Dursun Aras
SASinan Aydogdu
Sinan Aydogdu
Aim: The aim of the present study was to investigate the predictive value of preprocedural monocyte count-to-high-density lipoprotein cholesterol ratio (MHR) on development of in-stent restenosis in patients undergoing coronary bare-metal stent (BMS) implantation. Patients & methods: Data from 705 patients who had undergone BMS implantation and additional control coronary angiography were analyzed. Results: Patients were divided into three tertiles based on preprocedural MHR. Restenosis occurred in 59 patients (25%) in the lowest tertile, 84 (35%) in the middle tertile and 117 (50%) in the highest MHR tertile (p < 0.001). Using multiple logistic regression analysis, smoking, diabetes mellitus, stent length, preprocedural MHR and C-reactive protein levels emerged as independent predictors of in-stent restenosis. Conclusion: High preprocedural MHR is related to BMS restenosis.

5 November 2021 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
MAMehmet Kadri Akboga
Mehmet Kadri Akboga
ATAnkara- Turkey
Ankara- Turkey
SYSamet Yilmaz
Samet Yilmaz
RYRidvan Yalcin
Ridvan Yalcin
To evaluate the prognostic value of preprocedural CHA2DS2-VASc [congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, previous stroke or transient ischemic attack (TIA) (doubled), vascular disease, age 65–74 years, female gender] score in predicting high SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score and in-hospital mortality for non-atrial fibrillation (AF) patients presenting with non-ST elevation myocardial infarction (NSTEMI). The CHA2DS2-VASc score used to determine thromboembolic risks in AF was recently reported to predict major adverse clinical outcomes in patients with the acute coronary syndrome, irrespective of AF. A total of 906 patients with a diagnosis of NSTEMI who underwent coronary angiography were retrospectively enrolled and divided into three groups according to their SYNTAX scores (low, intermediate, and high). The CHA2DS2-VASc score of each patient was calculated. SYNTAX score had a significant positive correlation with the CHA2DS2-VASc score (r=0.320; p<0.001) in the Spearman correlation analysis. The CHA2DS2-VASc score [Odds ratio, 1.445; 95% confidence interval (CI), 1.268–1.648, p<0.001], left ventricular ejection fraction, creatinine, C-reactive protein, and high-density and low-density lipoprotein cholesterol levels were demonstrated to be independent predictors of high SYNTAX score. The CHA2DS2-VASc score [Hazard ratio (HR), 1.867; 95% CI: 1.462–2.384; p<0.001], the SYNTAX score (HR, 1.049; p=0.003), and age (HR, 1.057; p=0.002) were independently associated with higher risk of in-hospital mortality in a multiple Cox-regression model. Kaplan-Meier survival curves stratified by the CHA2DS2-VASc score (<4 vs. ≥4) also showed that higher CHA2DS2-VASc scores were associated with higher in-hospital mortality. In non-AF patients with NSTEMI, CHA2DS2-VASc and SYNTAX scores are useful for prognosis assessment and can be used to identify patients at higher risk for in-hospital mortality.

7 September 2021 in Acta Cardiologica
Verified
Journal Article
Closed access
MAMehmet Koray Adali
Mehmet Koray Adali
IBIpek Buber
Ipek Buber
KKKilic Kilic
Kilic Kilic
ATAnil Turkoz
Anil Turkoz
SYSamet Yilmaz
Samet Yilmaz
Inflammation plays a critical role in atherosclerosis. This study examines the effects of ticagrelor and clopidogrel on inflammatory parameters, obtained from complete blood count (CBC) and biochem...

27 March 2017 in Angiology
Verified
Journal Article
Closed access
SYSamet Yilmaz
Samet Yilmaz
MAMehmet Kadri Akboga
Mehmet Kadri Akboga
DADursun Aras
Dursun Aras
STSerkan Topaloglu
Serkan Topaloglu
The CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, previous stroke, vascular disease, age 65-74 years, female gender) score is used to estimate thromboembolic risk in atrial fibrillation (AF). Its usefulness in predicting in-stent restenosis (ISR) is unknown. We evaluated the predictive value of the CHA 2 DS 2 -VASc score in AF-free patients who have undergone stent implantation. A total of 1350 patients who underwent coronary angiography and successful bare-metal stent implantation were analyzed. The CHA 2 DS 2 -VASc score was calculated before percutaneous coronary intervention, and the association between the score and ISR was investigated. Patients (n = 700; mean age: 61.4 [8.7] years, 63% men) were divided in 2 subgroups according to the presence of ISR; 265 of 700 patients had ISR. Mean CHA 2 DS 2 -VASc score was significantly higher in the ISR (+) group than the ISR (−) group (3.7 [1.8] vs 2.1 [1.4], P < .001). According to multivariate logistic regression analysis, diabetes, hyperlipidemia, smoking, stent length, and CHA 2 DS 2 -VASc score were independent predictors of ISR. In conclusion, the CHA 2 DS 2 -VASc score may be useful as a new and simple tool to predict ISR.